Initial Public Offer fully subscribed with maximum A$8.5m raised
• Funds to be used to progress development of four first-in-class drugs addressing major global unmet needs:
• the high proportion of individuals where standard therapy based on statins fails to deliver target cholesterol levels
• secondary brain damage following stroke and traumatic brain injury contributing to permanent disability
• pain and inflammation associated with peripheral nerve crush injury such as sciatica
• autoimmune diseases, including psoriasis and multiple sclerosis
• High calibre management team and international Board with strong experience in advancing early-stage drugs to commercial outcomes
For more information, please download the attached PDF.
Download this document
